Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan in TNBC with Brain Metastases
NCT07458113Phase 2Not yet recruiting
- Sponsor
- Yale University
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer (TNBC), brain metastases, sponsored by Yale University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
triple-negative breast cancer (TNBC)brain metastases
Beyond the preview
Go deeper on NCT07458113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07458113.